| Literature DB >> 28930254 |
Mariana C Ferraz1, Renata A Mano2, Daniela H Oliveira3, Darla S V Maia4, Wladimir P Silva5, Lucielli Savegnago6, Eder J Lenardão7, Raquel G Jacob8.
Abstract
Background: The main constituents of Cymbopogonnardus (L) Rendle and C. citratus (DC) Stapfessential oils are (R)-citronellal and citral, respectively. Organochalcogen compounds can boost the biological activities of natural products.Entities:
Keywords: antibacterial; antioxidant; citronellal; foodborne bacteria; organochalcogen
Year: 2017 PMID: 28930254 PMCID: PMC5590075 DOI: 10.3390/medicines4020039
Source DB: PubMed Journal: Medicines (Basel) ISSN: 2305-6320
Figure 1Synthesis of nitrones derived from citronellal. (A) α-Phenylselanyl citronellal 3a, α-phenylthio citronellal 3b and nitrones 5a and 5b; (B) β-Phenylthio citronellal 8 and nitrone 5c; (C) Nitrone 5d.
Figure 2Synthesis of (3R,E)-3,7-dimethyl-2-(phenylselanyl)oct-6-enal oxime 10.
Figure 3Yields of nitrones derived from citronellal 5a–d and α-phenylselanyl oxime 10.
Antimicrobial activity of compounds 5a–d and 10 in the agar disk diffusion test.
| Bacteria ** | Inhibition Zone * (mm) Compounds | ||||||
|---|---|---|---|---|---|---|---|
| Streptomycin (10 µg) | 5a | 5b | 5c | 5d | 10 | 9e | |
| 21 | 18 | 19.5 | 26 | 31 | 21 | 21 | |
| 21 | 15 | 19.5 | 24 | 24.5 | 22 | 22 | |
| 26 | 21.5 | 18.5 | 24.5 | 29 | 19 | 19 | |
| 18 | 8.5 | 8.5 | 21.5 | 23 | 10.5 | 10.5 | |
| 13 | 8.5 | 8.5 | 24 | 23 | 9 | 9 | |
| 24 | 11 | 9 | 21.5 | 22.5 | 9 | 9 | |
Notes: * Results are the mean of two repetitions; ** Bacteria inoculated at the concentration of 1.0 × 108 CFU.mL−1.
Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of compounds 5a–d and 10.
| Compound | Bacteria ** | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC a,* | MBC a,* | MIC a,* | MBC a,* | MIC a,* | MBC a,* | MIC a,* | MBC a,* | MIC a,* | MBC a,* | MIC a,* | MBC a,* | |
| >0.65 | >0.65 | >0.65 | >0.65 | 0.48 | 0.59 | >0.65 | >0.65 | >0.65 | >0.65 | >0.65 | >0.65 | |
| >0.64 | >0.64 | 0.64 | >0.64 | 0.64 | >0.64 | >0.64 | >0.64 | >0.64 | >0.64 | >0.64 | >0.64 | |
| 0.69 | >0.69 | 0.61 | 0.69 | 0.69 | 0.69 | >0.69 | >0.69 | 0.61 | 0.61 | 0.52 | 0.52 | |
| 1.26 | 1.26 | 1.26 | 1.26 | >1.26 | >1.26 | 1.13 | 1.26 | 1.13 | 1.26 | 1.13 | 1.26 | |
| >0.70 | >0.70 | >0.70 | >0.70 | >0.70 | >0.70 | >0.70 | >0.70 | >0.70 | >0.70 | >0.70 | >0.70 | |
Notes: a Values in mM.mL−1; * Results are the mean of two repetitions; ** Bacteria inoculated at the concentration of 105 CFU.mL−1.
DPPH radical scavenging of compounds 5a and 5c.
| Concentration (μM) | Compounds | |
|---|---|---|
| 5a | 5c | |
| 100 | 2.43 ± 1.08 | 2.43 ± 0.61 |
| 500 | 20.31 ± 1.26 *** | 29.34 ± 1.00 *** |
Notes: Data are represented as mean ± SD (n = 3). The values are expressed in percentage of inhibition in relation to control. The asterisks represent significant difference (***) p < 0.001 when compared with control sample by Student–Newman–Keuls test for post-hoc comparison.
ABTS radical scavenging of compounds 5a–d and 10.
| Concentration (μM) | Compounds | ||||
|---|---|---|---|---|---|
| 5a | 5b | 5c | 5d | 10 | |
| 5 | nt | nt | nt | nt | 2.39 ± 0.57 |
| 10 | - | - | - | - | 27.81 ± 2.12 *** |
| 50 | 11.74 ± 0.47 *** | 9.69 ± 0.57 ** | 4.18 ± 1.23 | 0.30 ± 0.33 | 87.59 ± 4.81 *** |
| 100 | 22.84 ± 1.02 *** | 22.32 ± 1.65 *** | 11.60 ± 1.50 *** | 3.10 ± 0.48 *** | 94.03 ± 1.05 *** |
| 500 | 77.61 ± 0.81 *** | 73.92 ± 4.96 ** | 59.51 ± 4.16 *** | 17.05 ± 0.47 *** | |
| IC50 | 297.00 ± 1.00 | 315.30 ± 30.02 | 419.30 ± 35.80 | - | 25.00 ± 2.00 |
Notes: Data are represented as mean ± SD (n = 3). The values are expressed in percentage of inhibition in relation to control. IC50 = concentration compound required for 50% scavenging, in μM. The asterisks represent significant difference (**) p < 0.01; (***) p < 0.001 when compared with control sample by Student–Newman–Keuls test for post-hoc comparison. nt = not tested. x = sample blurred color.
Ferric ion reducing antioxidant power (FRAP) of compounds 5a–d and 10.
| Concentration (μM) | Compounds | ||||
|---|---|---|---|---|---|
| 5a | 5b | 5c | 5d | 10 | |
| Control | 0.118 ± 0.009 | 0.094 ± 0.026 | 0.071 ± 0.020 | 0.117 ± 0.009 | 0.071 ± 0.020 |
| 1 | - | nt | nt | 0.166 ± 0.008 | nt |
| 5 | 0.165 ± 0.007 | - | - | 0.280 ± 0.022 ** | - |
| 10 | 0.207 ± 0.019 * | 0.133 ± 0.097 | 0.153 ± 0.047 | 0.412 ± 0.055 *** | 0.084 ± 0.010 |
| 50 | 0.572 ± 0.023 *** | 0.256 ± 0.181 | 0.543 ± 0.047 *** | 1.198 ± 0.024 *** | 0.180 ± 0.008 *** |
| 100 | 1.039 ± 0.067 *** | 0.416 ± 0.234 | 1.121 ± 0.160 *** | 0.257 ± 0.007 *** | |
| 500 | 1.602 ± 0.408 *** | 1.291 ± 0.045 *** | |||
Notes: Data expressed mean ± SD (n = 3). The asterisks represent significant difference (*) p < 0.05; (**) p < 0.01; (***) p < 0.001 when compared with control sample (FRAP solution without compounds) by Student–Newman-Keuls test for post-hoc comparison. nt = not tested. x = absorbance above the spectrophotometer limit.
Assay of δ-ALA-D in liver, kidney, and brain of rats after treatment with compounds 5a–d and 10.
| Concentration (μM) | Compounds | ||||
|---|---|---|---|---|---|
| 5a | 5b | 5c | 5d | 10 | |
| control | 4,79 ± 0.87 | 4.79 ± 0.87 | 4.79 ± 0.87 | 4.30 ± 0.74 | 4.30 ± 0.74 |
| 10 | 4.99 ± 0.84 | 2.59 ± 0.29 *** | 4.63 ± 0.82 | 4.50 ± 0.60 | 4.90 ± 0.58 |
| 50 | 4.87 ± 0.67 | 0.42 ± 0.13 *** | 4.31 ± 0.81 | 4.22 ± 0.78 | 4.71 ± 0.53 |
| 100 | 4.71 ± 0.89 | 0.07 ± 0.02 *** | 4.12 ± 0.90 | 3.54 ± 0.84 | 4.57 ± 0.62 |
| 500 | 4.46 ± 0.80 | 0.03 ± 0.01 *** | 3.88 ± 0.87 | 2.84 ± 0.57 | 3.97 ± 0.82 |
| control | 1.01 ± 0.12 | 1.01 ± 0.12 | 1.01 ± 0.12 | 0.98 ± 0.11 | 0.98 ± 0.11 |
| 10 | 1.17 ± 0.05 | 1.08 ± 0.05 | 1.10 ± 0.12 | 1.02 ± 0.11 | 0.96 ± 0.12 |
| 50 | 1.17 ± 0.07 | 0.99 ± 0.07 | 1.02 ± 0.12 | 0.96 ± 0.12 | 0.95 ± 0.10 |
| 100 | 1.09 ± 0.08 | 0.68 ± 0.12 ** | 0.99 ± 0.10 | 0.89 ± 0.12 | 0.84 ± 0.10 |
| 500 | 0.90 ± 0.08 | 0.24 ± 0.03 *** | 0.90 ± 0.07 | 0.72 ± 0.07 | 0.61 ± 0.12 * |
| control | 0.30 ± 0.05 | 0.26 ± 0.05 | 0.30 ± 0.05 | 0.30 ± 0.05 | 0.30 ± 0.05 |
| 10 | 0.44 ± 0.09 | 0.30 ± 0.11 | 0.30 ± 0.10 | 0.29 ± 0.09 | 0.30 ± 0.10 |
| 50 | 0.42 ± 0.10 | 0.25 ± 0.05 | 0.28 ± 0.09 | 0.27 ± 0.10 | 0.28 ± 0.09 |
| 100 | 0.40 ± 0.11 | 0.18 ± 0.03 | 0.26 ± 0.08 | 0.26 ± 0.09 | 0.26 ± 0.08 |
| 500 | 0.36 ± 0.10 | 0.14 ± 0.04 | 0.26 ± 0.07 | 0.24 ± 0.08 | 0.26 ± 0.07 |
Notes: Data expressed mean ± SD (n = 3). The asterisks represent significant difference (**) p < 0.01; (***) p < 0.001 when compared with control sample by Student–Newman–Keuls test for post-hoc comparison.